TY - STD TI - American Cancer Society: Cancer Statistics Center. 2016. p. https://cancerstatisticscenter.cancer.org/. UR - https://cancerstatisticscenter.cancer.org/ ID - ref1 ER - TY - JOUR AU - Covens, A. AU - Carey, M. AU - Bryson, P. AU - Verma, S. AU - Fung Kee Fung, M. AU - Johnston, M. PY - 2002 DA - 2002// TI - Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer JO - Gynecol Oncol VL - 85 UR - https://doi.org/10.1006/gyno.2001.6552 DO - 10.1006/gyno.2001.6552 ID - Covens2002 ER - TY - JOUR AU - Gadducci, A. AU - Sartori, E. AU - Maggino, T. AU - Zola, P. AU - Landoni, F. AU - Fanucchi, A. PY - 1998 DA - 1998// TI - Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study JO - Gynecol Oncol VL - 68 UR - https://doi.org/10.1006/gyno.1997.4890 DO - 10.1006/gyno.1997.4890 ID - Gadducci1998 ER - TY - JOUR AU - Audeh, M. W. AU - Carmichael, J. AU - Penson, R. T. AU - Friedlander, M. AU - Powell, B. AU - Bell-McGuinn, K. M. PY - 2010 DA - 2010// TI - Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)60893-8 DO - 10.1016/S0140-6736(10)60893-8 ID - Audeh2010 ER - TY - JOUR AU - Ledermann, J. AU - Harter, P. AU - Gourley, C. AU - Friedlander, M. AU - Vergote, I. AU - Rustin, G. PY - 2014 DA - 2014// TI - Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70228-1 DO - 10.1016/S1470-2045(14)70228-1 ID - Ledermann2014 ER - TY - JOUR AU - Fong, P. C. AU - Yap, T. A. AU - Boss, D. S. AU - Carden, C. P. AU - Mergui-Roelvink, M. AU - Gourley, C. PY - 2010 DA - 2010// TI - Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.9589 DO - 10.1200/JCO.2009.26.9589 ID - Fong2010 ER - TY - JOUR PY - 2011 DA - 2011// TI - Integrated genomic analyses of ovarian carcinoma JO - Nature VL - 474 UR - https://doi.org/10.1038/nature10166 DO - 10.1038/nature10166 ID - ref7 ER - TY - STD TI - Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27:1449–55. ID - ref8 ER - TY - JOUR AU - Lupo, B. AU - Trusolino, L. PY - 1846 DA - 1846// TI - Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited JO - Biochim Biophys Acta VL - 2014 ID - Lupo1846 ER - TY - JOUR AU - Wang, M. AU - Wu, W. AU - Wu, W. AU - Rosidi, B. AU - Zhang, L. AU - Wang, H. PY - 2006 DA - 2006// TI - PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways JO - Nucleic Acids Res VL - 34 UR - https://doi.org/10.1093/nar/gkl840 DO - 10.1093/nar/gkl840 ID - Wang2006 ER - TY - JOUR AU - Hoeijmakers, J. H. PY - 2001 DA - 2001// TI - Genome maintenance mechanisms for preventing cancer JO - Nature VL - 411 UR - https://doi.org/10.1038/35077232 DO - 10.1038/35077232 ID - Hoeijmakers2001 ER - TY - JOUR AU - Pennington, K. P. AU - Swisher, E. M. PY - 2012 DA - 2012// TI - Hereditary ovarian cancer: beyond the usual suspects JO - Gynecol Oncol VL - 124 UR - https://doi.org/10.1016/j.ygyno.2011.12.415 DO - 10.1016/j.ygyno.2011.12.415 ID - Pennington2012 ER - TY - STD TI - Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2015:1–9. ID - ref13 ER - TY - JOUR AU - Randall, L. M. AU - Pothuri, B. PY - 2016 DA - 2016// TI - The genetic prediction of risk for gynecologic cancers JO - Gynecol Oncol VL - 141 UR - https://doi.org/10.1016/j.ygyno.2016.03.007 DO - 10.1016/j.ygyno.2016.03.007 ID - Randall2016 ER - TY - JOUR AU - Hall, J. M. AU - Lee, M. K. AU - Newman, B. AU - Morrow, J. E. AU - Anderson, L. A. AU - Huey, B. PY - 1990 DA - 1990// TI - Linkage of early-onset familial breast cancer to chromosome 17q21 JO - Science VL - 250 UR - https://doi.org/10.1126/science.2270482 DO - 10.1126/science.2270482 ID - Hall1990 ER - TY - JOUR AU - Alsop, K. AU - Fereday, S. AU - Meldrum, C. AU - DeFazio, A. AU - Emmanuel, C. AU - George, J. PY - 2012 DA - 2012// TI - BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.8545 DO - 10.1200/JCO.2011.39.8545 ID - Alsop2012 ER - TY - JOUR AU - Gourley, C. AU - Michie, C. O. AU - Roxburgh, P. AU - Yap, T. A. AU - Harden, S. AU - Paul, J. PY - 2010 DA - 2010// TI - Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.1082 DO - 10.1200/JCO.2009.25.1082 ID - Gourley2010 ER - TY - JOUR AU - Tan, D. S. AU - Yap, T. A. AU - Hutka, M. AU - Roxburgh, P. AU - Ang, J. AU - Banerjee, S. PY - 2013 DA - 2013// TI - Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.11.016 DO - 10.1016/j.ejca.2012.11.016 ID - Tan2013 ER - TY - JOUR AU - Risch, H. A. AU - McLaughlin, J. R. AU - Cole, D. E. AU - Rosen, B. AU - Bradley, L. AU - Fan, I. PY - 2006 DA - 2006// TI - Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada JO - J Natl Cancer Inst VL - 98 UR - https://doi.org/10.1093/jnci/djj465 DO - 10.1093/jnci/djj465 ID - Risch2006 ER - TY - JOUR AU - Risch, H. A. AU - McLaughlin, J. R. AU - Cole, D. E. AU - Rosen, B. AU - Bradley, L. AU - Kwan, E. PY - 2001 DA - 2001// TI - Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer JO - Am J Hum Genet VL - 68 UR - https://doi.org/10.1086/318787 DO - 10.1086/318787 ID - Risch2001 ER - TY - JOUR AU - Pal, T. AU - Permuth-Wey, J. AU - Betts, J. A. AU - Krischer, J. P. AU - Fiorica, J. AU - Arango, H. PY - 2005 DA - 2005// TI - BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases JO - Cancer VL - 104 UR - https://doi.org/10.1002/cncr.21536 DO - 10.1002/cncr.21536 ID - Pal2005 ER - TY - STD TI - Walsh CS. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 2015;137:343–50. ID - ref22 ER - TY - JOUR AU - Walsh, T. AU - Casadei, S. AU - Lee, M. K. AU - Pennil, C. C. AU - Nord, A. S. AU - Thornton, A. M. PY - 2011 DA - 2011// TI - Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1115052108 DO - 10.1073/pnas.1115052108 ID - Walsh2011 ER - TY - JOUR AU - Song, H. AU - Dicks, E. AU - Ramus, S. J. AU - Tyrer, J. P. AU - Intermaggio, M. P. AU - Hayward, J. PY - 2015 DA - 2015// TI - Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.61.2408 DO - 10.1200/JCO.2015.61.2408 ID - Song2015 ER - TY - JOUR AU - Hennessy, B. T. AU - Timms, K. M. AU - Carey, M. S. AU - Gutin, A. AU - Meyer, L. A. AU - Flake, D. D. PY - 2010 DA - 2010// TI - Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.2997 DO - 10.1200/JCO.2009.27.2997 ID - Hennessy2010 ER - TY - JOUR AU - Pennington, K. P. AU - Walsh, T. AU - Harrell, M. I. AU - Lee, M. K. AU - Pennil, C. C. AU - Rendi, M. H. PY - 2014 DA - 2014// TI - Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2287 DO - 10.1158/1078-0432.CCR-13-2287 ID - Pennington2014 ER - TY - JOUR AU - Cunningham, J. M. AU - Cicek, M. S. AU - Larson, N. B. AU - Davila, J. AU - Wang, C. AU - Larson, M. C. PY - 2014 DA - 2014// TI - Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status JO - Sci Rep VL - 4 UR - https://doi.org/10.1038/srep04026 DO - 10.1038/srep04026 ID - Cunningham2014 ER - TY - JOUR AU - Hampel, H. AU - Bennett, R. L. AU - Buchanan, A. AU - Pearlman, R. AU - Wiesner, G. L. PY - 2015 DA - 2015// TI - Guideline Development Group ACoMG, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment JO - Genet Med VL - 17 UR - https://doi.org/10.1038/gim.2014.147 DO - 10.1038/gim.2014.147 ID - Hampel2015 ER - TY - JOUR AU - Lu, K. H. AU - Wood, M. E. AU - Daniels, M. AU - Burke, C. AU - Ford, J. AU - Kauff, N. D. PY - 2014 DA - 2014// TI - American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.50.9257 DO - 10.1200/JCO.2013.50.9257 ID - Lu2014 ER - TY - JOUR AU - Daly, M. B. AU - Pilarski, R. AU - Axilbund, J. E. AU - Berry, M. AU - Buys, S. S. AU - Crawford, B. PY - 2016 DA - 2016// TI - Genetic/familial high-risk assessment: breast and ovarian, version 2.2015 JO - J Natl Compr Canc Netw VL - 14 ID - Daly2016 ER - TY - JOUR AU - Lancaster, J. M. AU - Powell, C. B. AU - Chen, L. M. AU - Richardson, D. L. AU - Committee, S. G. O. C. P. PY - 2015 DA - 2015// TI - Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions JO - Gynecol Oncol VL - 136 UR - https://doi.org/10.1016/j.ygyno.2014.09.009 DO - 10.1016/j.ygyno.2014.09.009 ID - Lancaster2015 ER - TY - JOUR AU - Blackburn, H. L. AU - Schroeder, B. AU - Turner, C. AU - Shriver, C. D. AU - Ellsworth, D. L. AU - Ellsworth, R. E. PY - 2015 DA - 2015// TI - Management of incidental findings in the era of next-generation sequencing JO - Curr Genomics VL - 16 UR - https://doi.org/10.2174/1389202916666150317232930 DO - 10.2174/1389202916666150317232930 ID - Blackburn2015 ER - TY - JOUR AU - Norquist, B. M. AU - Swisher, E. M. PY - 2015 DA - 2015// TI - More genes, more problems? Benefits and risks of multiplex genetic testing JO - Gynecol Oncol VL - 139 UR - https://doi.org/10.1016/j.ygyno.2015.10.013 DO - 10.1016/j.ygyno.2015.10.013 ID - Norquist2015 ER - TY - JOUR AU - Collins, V. R. AU - Meiser, B. AU - Ukoumunne, O. C. AU - Gaff, C. AU - St John, D. J. AU - Halliday, J. L. PY - 2007 DA - 2007// TI - The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing JO - Genet Med VL - 9 UR - https://doi.org/10.1097/GIM.0b013e31804b45db DO - 10.1097/GIM.0b013e31804b45db ID - Collins2007 ER - TY - JOUR AU - Watson, M. AU - Kash, K. M. AU - Homewood, J. AU - Ebbs, S. AU - Murday, V. AU - Eeles, R. PY - 2005 DA - 2005// TI - Does genetic counseling have any impact on management of breast cancer risk? JO - Genet Test VL - 9 UR - https://doi.org/10.1089/gte.2005.9.167 DO - 10.1089/gte.2005.9.167 ID - Watson2005 ER - TY - JOUR AU - Pal, T. AU - Lee, J. H. AU - Besharat, A. AU - Thompson, Z. AU - Monteiro, A. N. AU - Phelan, C. PY - 2014 DA - 2014// TI - Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers JO - Clin Genet VL - 85 UR - https://doi.org/10.1111/cge.12130 DO - 10.1111/cge.12130 ID - Pal2014 ER - TY - JOUR AU - Hadley, D. W. AU - Jenkins, J. F. AU - Dimond, E. AU - Carvalho, M. AU - Kirsch, I. AU - Palmer, C. G. PY - 2004 DA - 2004// TI - Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.06.128 DO - 10.1200/JCO.2004.06.128 ID - Hadley2004 ER - TY - JOUR AU - Schwartz, M. D. AU - Lerman, C. AU - Brogan, B. AU - Peshkin, B. N. AU - Halbert, C. H. AU - DeMarco, T. PY - 2004 DA - 2004// TI - Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.04.086 DO - 10.1200/JCO.2004.04.086 ID - Schwartz2004 ER - TY - JOUR AU - Calzone, K. A. AU - Prindiville, S. A. AU - Jourkiv, O. AU - Jenkins, J. AU - DeCarvalho, M. AU - Wallerstedt, D. B. PY - 2005 DA - 2005// TI - Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.04.050 DO - 10.1200/JCO.2005.04.050 ID - Calzone2005 ER - TY - JOUR AU - Armstrong, J. AU - Toscano, M. AU - Kotchko, N. AU - Friedman, S. AU - Schwartz, M. D. AU - Virgo, K. S. PY - 2015 DA - 2015// TI - Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study JO - JAMA Oncol VL - 1 UR - https://doi.org/10.1001/jamaoncol.2015.3048 DO - 10.1001/jamaoncol.2015.3048 ID - Armstrong2015 ER - TY - STD TI - Hilgart JS, Coles B, Iredale R. Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev. 2012;15. ID - ref41 ER - TY - JOUR AU - Braithwaite, D. AU - Emery, J. AU - Walter, F. AU - Prevost, A. T. AU - Sutton, S. PY - 2004 DA - 2004// TI - Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh017 DO - 10.1093/jnci/djh017 ID - Braithwaite2004 ER - TY - JOUR AU - DeMarco, T. A. AU - Peshkin, B. N. AU - Mars, B. D. AU - Tercyak, K. P. PY - 2004 DA - 2004// TI - Patient satisfaction with cancer genetic counseling: a psychometric analysis of the Genetic Counseling Satisfaction Scale JO - J Genet Couns VL - 13 UR - https://doi.org/10.1023/B:JOGC.0000035523.96133.bc DO - 10.1023/B:JOGC.0000035523.96133.bc ID - DeMarco2004 ER - TY - JOUR AU - Miller, C. E. AU - Krautscheid, P. AU - Baldwin, E. E. AU - Tvrdik, T. AU - Openshaw, A. S. AU - Hart, K. PY - 2014 DA - 2014// TI - Genetic counselor review of genetic test orders in a reference laboratory reduces unnecessary testing JO - Am J Med Genet A VL - 164A UR - https://doi.org/10.1002/ajmg.a.36453 DO - 10.1002/ajmg.a.36453 ID - Miller2014 ER - TY - JOUR AU - Cragun, D. AU - Camperlengo, L. AU - Robinson, E. AU - Caldwell, M. AU - Kim, J. AU - Phelan, C. PY - 2015 DA - 2015// TI - Differences in BRCA counseling and testing practices based on ordering provider type JO - Genet Med VL - 17 UR - https://doi.org/10.1038/gim.2014.75 DO - 10.1038/gim.2014.75 ID - Cragun2015 ER - TY - JOUR AU - Weitzel, J. N. AU - McCaffrey, S. M. AU - Nedelcu, R. AU - MacDonald, D. J. AU - Blazer, K. R. AU - Cullinane, C. A. PY - 2003 DA - 2003// TI - Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis JO - Arch Surg VL - 138 UR - https://doi.org/10.1001/archsurg.138.12.1323 DO - 10.1001/archsurg.138.12.1323 ID - Weitzel2003 ER - TY - STD TI - Lynparza prescribing information. Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2014. Available at http://www.azpicentral.com/Lynparza/pi_lynparza.pdf#page=1. UR - http://www.azpicentral.com/Lynparza/pi_lynparza.pdf#page=1 ID - ref47 ER - TY - STD TI - Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154-2164. ID - ref48 ER - TY - JOUR AU - Vasen, H. F. AU - Abdirahman, M. AU - Brohet, R. AU - Langers, A. M. AU - Kleibeuker, J. H. AU - Kouwen, M. PY - 2010 DA - 2010// TI - One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome JO - Gastroenterology VL - 138 UR - https://doi.org/10.1053/j.gastro.2010.02.053 DO - 10.1053/j.gastro.2010.02.053 ID - Vasen2010 ER - TY - JOUR AU - Schmeler, K. M. AU - Lynch, H. T. AU - Chen, L. M. AU - Munsell, M. F. AU - Soliman, P. T. AU - Clark, M. B. PY - 2006 DA - 2006// TI - Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa052627 DO - 10.1056/NEJMoa052627 ID - Schmeler2006 ER - TY - JOUR AU - Engel, C. AU - Rahner, N. AU - Schulmann, K. AU - Holinski-Feder, E. AU - Goecke, T. O. AU - Schackert, H. K. PY - 2010 DA - 2010// TI - Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer JO - Clin Gastroenterol Hepatol VL - 8 UR - https://doi.org/10.1016/j.cgh.2009.10.003 DO - 10.1016/j.cgh.2009.10.003 ID - Engel2010 ER - TY - JOUR AU - Abkevich, V. AU - Timms, K. M. AU - Hennessy, B. T. AU - Potter, J. AU - Carey, M. S. AU - Meyer, L. A. PY - 2012 DA - 2012// TI - Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer JO - Br J Cancer VL - 107 UR - https://doi.org/10.1038/bjc.2012.451 DO - 10.1038/bjc.2012.451 ID - Abkevich2012 ER - TY - JOUR AU - Birkbak, N. J. AU - Wang, Z. C. AU - Kim, J. Y. AU - Eklund, A. C. AU - Li, Q. AU - Tian, R. PY - 2012 DA - 2012// TI - Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-11-0206 DO - 10.1158/2159-8290.CD-11-0206 ID - Birkbak2012 ER - TY - JOUR AU - Popova, T. AU - Manie, E. AU - Rieunier, G. AU - Caux-Moncoutier, V. AU - Tirapo, C. AU - Dubois, T. PY - 2012 DA - 2012// TI - Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-1470 DO - 10.1158/0008-5472.CAN-12-1470 ID - Popova2012 ER - TY - JOUR AU - Schwarz, R. F. AU - Ng, C. K. AU - Cooke, S. L. AU - Newman, S. AU - Temple, J. AU - Piskorz, A. M. PY - 2015 DA - 2015// TI - Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis JO - PLoS Med VL - 12 UR - https://doi.org/10.1371/journal.pmed.1001789 DO - 10.1371/journal.pmed.1001789 ID - Schwarz2015 ER - TY - JOUR AU - Lin, K. AU - Sun, J. AU - Maloney, L. AU - Goble, S. AU - Oza, A. AU - Coleman, R. AU - Scott, C. AU - Robillard, L. AU - Mann, E. AU - Isaacson, J. AU - Harding, T. PY - 2015 DA - 2015// TI - 2710 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/S0959-8049(16)31469-1 DO - 10.1016/S0959-8049(16)31469-1 ID - Lin2015 ER - TY - JOUR AU - Gelmon, K. A. AU - Tischkowitz, M. AU - Mackay, H. AU - Swenerton, K. AU - Robidoux, A. AU - Tonkin, K. PY - 2011 DA - 2011// TI - Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70214-5 DO - 10.1016/S1470-2045(11)70214-5 ID - Gelmon2011 ER - TY - JOUR AU - Kummar, S. AU - Oza, A. M. AU - Fleming, G. F. AU - Sullivan, D. M. AU - Gandara, D. R. AU - Naughton, M. J. PY - 2015 DA - 2015// TI - Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer JO - Clin Cancer Res. VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2565 DO - 10.1158/1078-0432.CCR-14-2565 ID - Kummar2015 ER - TY - JOUR AU - Swisher, E. M. AU - Lin, K. K. AU - Oza, A. M. AU - Scott, C. L. AU - Giordano, H. AU - Sun, J. PY - 2017 DA - 2017// TI - Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30559-9 DO - 10.1016/S1470-2045(16)30559-9 ID - Swisher2017 ER - TY - JOUR AU - Ledermann, J. AU - Harter, P. AU - Gourley, C. AU - Friedlander, M. AU - Vergote, I. AU - Rustin, G. PY - 2012 DA - 2012// TI - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1105535 DO - 10.1056/NEJMoa1105535 ID - Ledermann2012 ER - TY - JOUR AU - Collins, F. S. AU - Varmus, H. PY - 2015 DA - 2015// TI - A new initiative on precision medicine JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMp1500523 DO - 10.1056/NEJMp1500523 ID - Collins2015 ER - TY - JOUR AU - Borzekowski, D. L. AU - Guan, Y. AU - Smith, K. C. AU - Erby, L. H. AU - Roter, D. L. PY - 2014 DA - 2014// TI - The Angelina effect: immediate reach, grasp, and impact of going public JO - Genetics Med VL - 16 UR - https://doi.org/10.1038/gim.2013.181 DO - 10.1038/gim.2013.181 ID - Borzekowski2014 ER - TY - JOUR AU - Meyer, L. A. AU - Anderson, M. E. AU - Lacour, R. A. AU - Suri, A. AU - Daniels, M. S. AU - Urbauer, D. L. PY - 2010 DA - 2010// TI - Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities JO - Obstet Gynecol VL - 115 UR - https://doi.org/10.1097/AOG.0b013e3181da08d7 DO - 10.1097/AOG.0b013e3181da08d7 ID - Meyer2010 ER - TY - JOUR AU - Metcalfe, K. A. AU - Fan, I. AU - McLaughlin, J. AU - Risch, H. A. AU - Rosen, B. AU - Murphy, J. PY - 2009 DA - 2009// TI - Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study JO - Gynecol Oncol VL - 112 UR - https://doi.org/10.1016/j.ygyno.2008.10.007 DO - 10.1016/j.ygyno.2008.10.007 ID - Metcalfe2009 ER - TY - JOUR AU - Buchanan, A. H. AU - Rahm, A. K. AU - Williams, J. L. PY - 2016 DA - 2016// TI - Alternate service delivery models in cancer genetic counseling: a mini-review JO - Front Oncol VL - 6 UR - https://doi.org/10.3389/fonc.2016.00120 DO - 10.3389/fonc.2016.00120 ID - Buchanan2016 ER - TY - BOOK AU - Watson MU, C. H. AU - Tillmanns, T. AU - Reed, M. E. AU - Smiley, L. AU - Covington, R. PY - 2016 DA - 2016// TI - The implementation of video-assisted genetic counseling for ovarian, fallopian, and peritoneal cancer patients Society of Gynecologic Oncology Annual Meeting on Women’s Cancer San Diego ID - Watson MU2016 ER - TY - JOUR AU - Stadler, Z. K. AU - Battaglin, F. AU - Middha, S. AU - Hechtman, J. F. AU - Tran, C. AU - Cercek, A. PY - 2016 DA - 2016// TI - Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.1067 DO - 10.1200/JCO.2015.65.1067 ID - Stadler2016 ER - TY - JOUR AU - Hampel, H. AU - Frankel, W. L. AU - Martin, E. AU - Arnold, M. AU - Khanduja, K. AU - Kuebler, P. PY - 2005 DA - 2005// TI - Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043146 DO - 10.1056/NEJMoa043146 ID - Hampel2005 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - STD TI - A.N. Fader LAD, D.K. Armstrong, E.J. Tanner III, J. Uram, A. Eyring, H. Wang, G. Fisher, T. Greten and D. Le. Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer: Late-breaking abstract sessions 3; 2016. ID - ref70 ER - TY - STD TI - James X. Sun GF, Kai Wang, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, Doron Lipson, Roman Yelensky. Abstract 1893: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9. San Diego, CA 2014. ID - ref71 ER - TY - JOUR AU - Chiang, J. W. AU - Karlan, B. Y. AU - Cass, L. AU - Baldwin, R. L. PY - 2006 DA - 2006// TI - BRCA1 promoter methylation predicts adverse ovarian cancer prognosis JO - Gynecol Oncol VL - 101 UR - https://doi.org/10.1016/j.ygyno.2005.10.034 DO - 10.1016/j.ygyno.2005.10.034 ID - Chiang2006 ER - TY - STD TI - Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter studycomparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372–9. ID - ref73 ER - TY - STD TI - Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87–97. ID - ref74 ER - TY - STD TI - Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;137:386–91. ID - ref75 ER - TY - STD TI - Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015; 33:244–50. ID - ref76 ER -